408 related articles for article (PubMed ID: 32026210)
1. Molecular basis of clonal evolution in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2020 Apr; 111(4):496-511. PubMed ID: 32026210
[TBL] [Abstract][Full Text] [Related]
2. [Treatment strategies for multiple myeloma based on molecular pathogenesis].
Furukawa Y
Rinsho Ketsueki; 2022; 63(9):1167-1179. PubMed ID: 36198542
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of multiple myeloma.
Furukawa Y; Kikuchi J
Int J Clin Oncol; 2015 Jun; 20(3):413-22. PubMed ID: 25953678
[TBL] [Abstract][Full Text] [Related]
4. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M; Nickel K; Högner M; Bassermann F
Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
6. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
7. Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma.
Suzuki K; Nishiwaki K; Yano S
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435539
[TBL] [Abstract][Full Text] [Related]
8. Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson DC; Lenive O; Mitchell J; Jackson G; Owen R; Drayson M; Cook G; Jones JR; Pawlyn C; Davies FE; Walker BA; Wardell C; Gregory WM; Cairns D; Morgan GJ; Houlston RS; Kaiser MF
Blood; 2017 Oct; 130(14):1639-1643. PubMed ID: 28827410
[TBL] [Abstract][Full Text] [Related]
9. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
Melchor L; Brioli A; Wardell CP; Murison A; Potter NE; Kaiser MF; Fryer RA; Johnson DC; Begum DB; Hulkki Wilson S; Vijayaraghavan G; Titley I; Cavo M; Davies FE; Walker BA; Morgan GJ
Leukemia; 2014 Aug; 28(8):1705-15. PubMed ID: 24480973
[TBL] [Abstract][Full Text] [Related]
10. Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.
Hansmann L; Han A; Penter L; Liedtke M; Davis MM
Cancer Immunol Res; 2017 Sep; 5(9):744-754. PubMed ID: 28768640
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.
Dutta AK; Hewett DR; Fink JL; Grady JP; Zannettino ACW
Br J Haematol; 2017 Jul; 178(2):196-208. PubMed ID: 28466550
[TBL] [Abstract][Full Text] [Related]
12. [Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].
Ding F; Zhu P; Wu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1513-6. PubMed ID: 26524068
[TBL] [Abstract][Full Text] [Related]
13. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming.
Liang Y; He H; Wang W; Wang H; Mo S; Fu R; Liu X; Song Q; Xia Z; Wang L
Mol Cancer; 2022 Sep; 21(1):182. PubMed ID: 36131282
[TBL] [Abstract][Full Text] [Related]
14. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
15. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G; Anderson KC
CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
[TBL] [Abstract][Full Text] [Related]
16. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
18. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
20. Impact of Clonal Heterogeneity in Multiple Myeloma.
Schinke C; Rasche L; Raab MS; Weinhold N
Hematol Oncol Clin North Am; 2024 Apr; 38(2):461-476. PubMed ID: 38195308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
